COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

18/04/2018 - 13:30

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks - - Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved - CAMBRIDGE, Mass., April 18, 2018 (GLOBE [...]

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

18/04/2018 - 13:01

Randomized CANTATA trial open for enrollment SOUTH SAN FRANCISCO, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA ), a clinical stage biotechnology company focused on the development [...]

AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018

18/04/2018 - 13:00

ALACHUA, Fla., April 18, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN ), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that it will report first [...]

EyePoint Pharmaceuticals’ YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

18/04/2018 - 13:00

WATERTOWN, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT ) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, [...]

AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa

18/04/2018 - 13:00

GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus ( [...]

Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting

18/04/2018 - 13:00

TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq: TRIL ) (TSX: TRIL ), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced [...]

Capital Senior Living Corporation Announces Release Date for First Quarter 2018 Financial Results

18/04/2018 - 12:00

DALLAS, April 18, 2018 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (NYSE: CSU ) will host a conference call with senior management to discuss the Company’s first quarter 2018 financial results. The call will [...]

Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure

18/04/2018 - 12:00

NEW YORK and MELBOURNE, Australia, April 18, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today provided an update on the Phase 3 and Phase 2b clinical trials of the Company's proprietary [...]

HealthLynked Corp. Announces Software Update Allowing Users Complete Control of Medical Record Sharing and Access

18/04/2018 - 11:00

NAPLES, Fla., April 18, 2018 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB:HLYK) today announced release of its access control panel feature. A key service to members of the HealthLynked Network is the ability to share [...]

Dr. Michael K. Pugsley Joins Veritas Pharma’s Advisory Board

18/04/2018 - 09:50

VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) , (“Veritas” or the “Company”) is pleased to announce that Dr. Michael K. Pugsley PhD, FBPhS, [...]

Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole

18/04/2018 - 07:16

Basel, Switzerland, April 18, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its license partner Asahi Kasei Pharma Corporation ("Asahi Kasei Pharma") has started enrollment in a clinical phase 3 [...]

Curetis: Novel Products and Study Data to be Presented at ECCMID 2018

18/04/2018 - 07:02

Curetis: Novel Products and Study Data to be Presented at ECCMID 2018 Introduction of Unyvero UTI Application Cartridge Update on A30 RQ Analyzer to be provided MGI/Curetis NGS Solution for Molecular Microbiology to be [...]

GUERBET : 1st quarter 2018 revenue

18/04/2018 - 07:01

€196.5 million at constant exchange rates: -3.2% Villepinte, April 18, 2018 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €183.2 million [...]

GUERBET : Chiffre d'affaires 1er trimestre 2018

18/04/2018 - 07:01

196,5 M€ à taux de change constant : -3,2% Villepinte, le 18 avril 2018 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie un chiffre d'affaires de [...]

GUERBET : GEAR 2023 strategic plan

18/04/2018 - 07:01

Villepinte, April 18, 2018 - Guerbet ( the "Company "), a global specialist in contrast agents and solutions for medical imaging, has released today its GEAR 2023 strategic plan. About Guerbet Guerbet is a leading [...]

GUERBET : Plan stratégique GEAR 2023

18/04/2018 - 07:01

Villepinte, 18 avril 2018 - Guerbet (la « Société ») , spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, publie aujourd'hui son plan stratégique GEAR 2023. A propos de Guerbet Guerbet [...]

DiaMedica Issues Stock Option Grants

18/04/2018 - 03:00

MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the " Company ") (TSX-V: DMA ) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and directors of the [...]

ALK’s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet

18/04/2018 - 03:00

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has agreed a price with authorities and secured a listing on Japan’s National Health Insurance [...]

Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

18/04/2018 - 00:26

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and [...]